Journal
SCIENCE ADVANCES
Volume 7, Issue 1, Pages -Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/sciadv.abb6104
Keywords
-
Categories
Funding
- Natural Science Foundation Programs [81130026, 81773352]
- Innovation Team Building Program of Chongqing University [CXTDG201602020]
- Outstanding Youth Development Program of Third Military Medical University
Ask authors/readers for more resources
IR-26 is a novel fluorescent dye that preferentially accumulates in the mitochondria of AML cells, exerting targeted therapeutic effects and potential for real-time monitoring of AML cells. It represents an all-in-one agent for AML targeting, detection, and therapy.
Acute myeloid leukemia (AML) is a deadly hematological malignancy with frequent disease relapse. The biggest challenge for AML therapy is the lack of methods to target and kill the heterogeneous leukemia cells, which lead to disease relapse. Here, we describe a near-infrared (NIR) fluorescent dye, IR-26, which preferentially accumulates in the mitochondria of AML cells, depending on the hyperactive glycolysis of malignant cell, and simultaneously impairs oxidative phosphorylation (OXPHOS) to exert targeted therapeutic effects for AML cells. In particular, IR-26 also exhibits potential for real-time monitoring of AML cells with an in vivo flow cytometry (IVFC) system. Therefore, IR-26 represents a novel all-in-one agent for the integration of AML targeting, detection, and therapy, which may help to monitor disease progression and treatment responses, prevent unnecessary delays in administering upfront therapy, and improve therapeutic efficiency to the residual AML cells, which are responsible for disease relapse.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available